Antibody Titers and Immune Response to Diphtheria-Tetanus-Pertussis and Measles-Mumps-Rubella Vaccination in Children Treated for Acute Lymphoblastic Leukemia
Authors:
- Tugba Erener ErcanTETugba Erener Ercan
- Lebriz Yüksel SoycanLSLebriz Yüksel Soycan
- Hilmi ApakHAHilmi Apak
- Tiraje CelkanTCTiraje Celkan
- Alp OzkanAOAlp Ozkan
- Emine AkdenizliEAEmine Akdenizli
- Ozgur KasapçopurOKOzgur Kasapçopur
- Inci YildizIYInci Yildiz
- 1 May 2005
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 27 (5) , 273-277
Abstract
The objective of this study was to investigate the diphtheria-tetanus-pertussis and/or measles-mumps antibody titers before and after vaccination at various time points of acute lymphoblastic leukemia (ALL) therapy and to suggest an appropriate vaccination approach for ALL patients. The authors studied 37 ALL patients and 14 healthy control subjects, divided into three groups. In group 1 (newly diagnosed patients), baseline anti-diphtheria, anti-tetanus, and anti-pertussis titers were determined. Patients in group 2 (on maintenance chemotherapy) and group 3 (patients not receiving therapy for 3-6 months) were vaccinated with diphtheria-tetanus with or without acellular pertussis; group 3 and control subjects were also given measles-mumps-rubella vaccine. Preimmunization and 1-month postimmunization titers were drawn. Preimmunization anti-diphtheria and anti-tetanus antibody titers between the groups and the controls were statistically similar. The seropositivity rate for anti-measles antibody in group 3 was significantly lower than controls. After vaccination, all of the patients developed protective anti-diphtheria and anti-tetanus antibody titers. The seroconversion rates of group 3 and controls for anti-measles and anti-mumps antibodies were statistically similar. The results showed that patients on maintenance therapy and after cessation of therapy made good antibody responses to diphtheria and tetanus toxoids, but response to measles and mumps vaccines was not as sufficient as toxoid vaccines. Children with ALL can receive the appropriate vaccines during and after maintenance treatment.Keywords
This publication has 25 references indexed in Scilit:
- Childhood acute lymphoblastic leukaemia – current status and future perspectivesThe Lancet Oncology, 2001
- Immunization of transplant recipientsBone Marrow Transplantation, 1999
- Tetanus immunity in autologous bone marrow and blood stem cell transplant recipientsBone Marrow Transplantation, 1998
- A randomized comparison between early and late vaccination with tetanus toxoid vaccine after allogeneic BMTBone Marrow Transplantation, 1997
- A National Survey of Immunization Practices Following Allogeneic Bone Marrow TransplantationJAMA, 1997
- Loss of protective immunity to polio, diphtheria andHaemophilus influenzaetype b after allogeneic bone marrow transplantationAPMIS, 1996
- Immunodeficiency in long-term survivors of acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster therapyThe Journal of Pediatrics, 1995
- Long-term immunity to measles, mumps, and rubella after allogeneic bone marrow transplantationBlood, 1994
- Recovery of blood b-lymphocytes and serum immunoglobulins after chemotherapy for childhood acute lymphoblastic leukemiaCancer, 1992
- Immunization Response Varies With Intensity of Acute Lymphoblastic Leukemia TherapyArchives of Pediatrics & Adolescent Medicine, 1991